These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 21886014)

  • 1. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
    Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
    Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review.
    Kwee RM
    Radiology; 2010 Mar; 254(3):707-17. PubMed ID: 20177086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of response to neoadjuvant therapy in esophageal cancer: an updated systematic review of diagnostic accuracy of endoscopic ultrasonography and fluorodeoxyglucose positron emission tomography.
    Ngamruengphong S; Sharma VK; Nguyen B; Das A
    Dis Esophagus; 2010 Apr; 23(3):216-31. PubMed ID: 19515185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.
    Wang Y; Zhang C; Liu J; Huang G
    Breast Cancer Res Treat; 2012 Jan; 131(2):357-69. PubMed ID: 21960111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.
    Westerterp M; van Westreenen HL; Reitsma JB; Hoekstra OS; Stoker J; Fockens P; Jager PL; Van Eck-Smit BL; Plukker JT; van Lanschot JJ; Sloof GW
    Radiology; 2005 Sep; 236(3):841-51. PubMed ID: 16118165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis.
    Mghanga FP; Lan X; Bakari KH; Li C; Zhang Y
    Clin Breast Cancer; 2013 Aug; 13(4):271-9. PubMed ID: 23714689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive values of interim
    Han S; Kim YI; Woo S; Kim TH; Ryu JS
    Ann Nucl Med; 2021 Apr; 35(4):447-457. PubMed ID: 33471289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
    Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
    Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
    Cong L; Wang S; Gao T; Hu L
    Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
    Sloof GW
    Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.
    Suttie SA; Welch AE; Park KG
    Eur J Surg Oncol; 2009 Oct; 35(10):1019-29. PubMed ID: 19232881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
    Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
    Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
    Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
    Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.